3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Gastrointestinal
1
Breast
1
Conditions
Carcinoma, Non-Small-Cell Lung
328
Lung Neoplasms
158
Pancreatic Neoplasms
30
Adenocarcinoma of Lung
27
Colorectal Neoplasms
26
Neoplasms
24
Small Cell Lung Carcinoma
21
Breast Neoplasms
17
Neoplasm Metastasis
15
Mesothelioma, Malignant
14
Ovarian Neoplasms
12
Adenocarcinoma, Bronchiolo-Alveolar
12
Mesothelioma
10
Stomach Neoplasms
9
Colonic Neoplasms
9
Squamous Cell Carcinoma of Head and Neck
8
Carcinoma
8
Urinary Bladder Neoplasms
7
Triple Negative Breast Neoplasms
7
Sarcoma
7
Prostatic Neoplasms
7
Head and Neck Neoplasms
7
Rectal Neoplasms
6
Non-Squamous Non-Small Cell Lung Cancer
6
Melanoma
6
Lymphoma, Non-Hodgkin
6
Esophageal Neoplasms
6
Lymphoma
5
Thoracic Neoplasms
4
Parkinson Disease 4, Autosomal Dominant Lewy Body
4
Interventions
Cyclophosphamide
7
pembrolizumab
6
Radiotherapy
6
Cisplatin
6
Sunitinib
5
Carboplatin
5
Paclitaxel
4
Thymectomy
3
130-nm albumin-bound paclitaxel
3
selinexor
2
lenvatinib
2
fludarabine
2
Taxes
2
Robotic Surgical Procedures
2
Ramucirumab
2
Prednisone
2
Pemetrexed
2
Octreotide
2
Nivolumab
2
N,1,4,4-tetramethyl-8-((4-(4-methylpiperazin-1-yl)phenyl)amino)-4,5-dihydro-1H-pyrazolo(4,3-h)quinazoline-3-carboxamide
2
Methylprednisolone
2
Imatinib Mesylate
2
Etoposide
2
Erlotinib Hydrochloride
2
Drug Therapy
2
Doxorubicin
2
Chemoradiotherapy
2
Celecoxib
2
zimberelimab
1
vorolanib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Thymoma
×
Gemcitabine
×
Thoracic
×
Clear all
NCT03102320
2022-06-30
ARCS-Multi
Bayer
Phase 1
Completed
173 enrolled